Journal
BLOOD
Volume 122, Issue 24, Pages 3892-3898Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-05-498311
Keywords
-
Categories
Funding
- National Institutes of Health [R01 HL097819, R01 DK056638, R01 HL116340]
Ask authors/readers for more resources
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review. (Blood. 2013;122(24):3892-3898)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available